210 related articles for article (PubMed ID: 28033228)
1. SUB-TENON TRIAMCINOLONE ACETONIDE INJECTION IN A PREGNANT PATIENT WITH VOGT-KOYANAGI-HARADA DISEASE.
Nakamura T; Keino H; Okada AA
Retin Cases Brief Rep; 2018 Fall; 12(4):375-378. PubMed ID: 28033228
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.
Andrade RE; Muccioli C; Farah ME; Nussenblatt RB; Belfort R
Am J Ophthalmol; 2004 Mar; 137(3):572-4. PubMed ID: 15013890
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome.
Karacorlu M; Arf Karacorlu S; Ozdemir H
Eur J Ophthalmol; 2006; 16(3):481-3. PubMed ID: 16761256
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease.
Khalifa Y; Loh AR; Acharya NR
Ocul Immunol Inflamm; 2009; 17(6):431-3. PubMed ID: 20001265
[TBL] [Abstract][Full Text] [Related]
5. Suprachoroidal triamcinolone acetonide injection: a novel therapy for serous retinal detachment due to Vogt-Koyanagi Harada disease.
Tabl AA; Elsayed MA; Tabl MA
Eur J Ophthalmol; 2022 Nov; 32(6):3482-3488. PubMed ID: 35266801
[TBL] [Abstract][Full Text] [Related]
6. Management of ocular complications of Vogt-Koyanagi-Harada syndrome.
Perente I; Utine CA; Cakir H; Kaya V; Tutkun IT; Yilmaz OF
Int Ophthalmol; 2009 Feb; 29(1):33-7. PubMed ID: 17952373
[TBL] [Abstract][Full Text] [Related]
7. Role of intravitreal triamcinolone as an adjuvant in the management of Vogt-Koyanagi-Harada disease.
Moreker MR; Lodhi SA; Pathengay A
Indian J Ophthalmol; 2007; 55(6):479-80. PubMed ID: 17951914
[No Abstract] [Full Text] [Related]
8. Posterior subtenon triamcinolone acetonide injection as a primary treatment in eyes with acute Vogt-Koyanagi-Harada disease.
Hosoda Y; Hayashi H; Kuriyama S
Br J Ophthalmol; 2015 Sep; 99(9):1211-4. PubMed ID: 25792626
[TBL] [Abstract][Full Text] [Related]
9. A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine.
Nakayama M; Okada AA; Hayashi I; Ando Y; Watanabe T; Keino H
Ocul Immunol Inflamm; 2023 Feb; 31(2):462-467. PubMed ID: 35167414
[TBL] [Abstract][Full Text] [Related]
10. BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE: A Novel Swept-Source Optical Coherence Tomography Analysis.
Agarwal A; Freund KB; Kumar A; Aggarwal K; Sharma D; Katoch D; Bansal R; Gupta V;
Retina; 2021 Apr; 41(4):774-783. PubMed ID: 32833410
[TBL] [Abstract][Full Text] [Related]
11. Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease.
Lu S; Taban M
Digit J Ophthalmol; 2016; 22(2):54-7. PubMed ID: 27582676
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pulse corticosteroid therapy for vogt-koyanagi-harada disease assessed by optical coherence tomography.
Yamanaka E; Ohguro N; Yamamoto S; Nakagawa Y; Imoto Y; Tano Y
Am J Ophthalmol; 2002 Sep; 134(3):454-6. PubMed ID: 12208266
[TBL] [Abstract][Full Text] [Related]
13. Long-term Outcomes of Limited Vogt-Koyanagi-Harada Syndrome.
Chew SK; Levy J; Rogers S; Lim LL
Am J Ophthalmol; 2016 Jul; 167():52-6. PubMed ID: 27066721
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada disease.
O'Keefe GA; Rao NA
Surv Ophthalmol; 2017; 62(1):1-25. PubMed ID: 27241814
[TBL] [Abstract][Full Text] [Related]
15. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
Kikuchi R; Kawagoe T; Hotta K
BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
[TBL] [Abstract][Full Text] [Related]
16. [Vogt-Koyanagi-Harada disease complicated by subretinal neovessels].
Lepvrier-Guibal N; Korobelnik JF; Xuan TH
J Fr Ophtalmol; 1995; 18(4):305-11. PubMed ID: 7769166
[TBL] [Abstract][Full Text] [Related]
17. FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety.
Heo JW; Cho BJ; Goldstein DA; Sepah YJ; Do DV; Nguyen QD
Retina; 2016 Nov; 36(11):2124-2131. PubMed ID: 27333235
[TBL] [Abstract][Full Text] [Related]
18. Vogt-Koyanagi-Harada syndrome associated with bilateral serous macular detachments responsive to immunomodulatory therapy.
Gallagher MJ; Yilmaz T; Foster CS
Ophthalmic Surg Lasers Imaging; 2009; 40(3):345-7. PubMed ID: 19485308
[No Abstract] [Full Text] [Related]
19. RETINAL PIGMENT EPITHELIUM UNDULATIONS IN ACUTE STAGE OF VOGT-KOYANAGI-HARADA DISEASE: Biomarker for Functional Outcomes After High-Dose Steroid Therapy.
Hashizume K; Imamura Y; Fujiwara T; Machida S; Ishida M; Kurosaka D
Retina; 2016 Feb; 36(2):415-21. PubMed ID: 26352553
[TBL] [Abstract][Full Text] [Related]
20. Vogt-Koyanagi-Harada syndrome (uveomeningoencephalitic syndrome).
Manethova K; Ernest J; Hrevus M
Eur J Ophthalmol; 2017 Jan; 27(1):e5-e8. PubMed ID: 28009404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
